Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound
Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have a...
Gespeichert in:
Veröffentlicht in: | Viruses 2024-06, Vol.16 (6) |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 6 |
container_start_page | |
container_title | Viruses |
container_volume | 16 |
creator | Erickson, Mauri Boone, Tyler J Nadworny, Patricia L |
description | Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary. |
doi_str_mv | 10.3390/v16060959 |
format | Article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A799645126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A799645126</galeid><sourcerecordid>A799645126</sourcerecordid><originalsourceid>FETCH-LOGICAL-g676-c9de6a42a9b08fdd0c6c42f9a87245ab0b25068507bcb4a4fbe2913d8222b30f3</originalsourceid><addsrcrecordid>eNptjE1LxDAYhIMouK4e_AcBr7a-TZO077EWVxcW9uB6kmVJ0qRE-qH9Av-99eOwB5nDPAwzQ8h1BGEcI9xNkQQJKPCELCJEDDhG4vSIz8lF378BSImQLMh91gx-8p2qaGa-afikraNZ-dqPOhT79fYH5P6WKvrS-I_R0mdfTbajeVu_t2NTXJIzp6reXv35kuxWD7v8KdhsH9d5tglKmcjAYGGl4kyhhtQVBRhpOHOo0oRxoTRoJkCmAhJtNFfcacswiouUMaZjcPGS3PzelqqyB9-4duiUqX1vDlmCKLmImJxb4T-tWYWtvWkb6_ycHw2-AN7KWPU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Erickson, Mauri ; Boone, Tyler J ; Nadworny, Patricia L</creator><creatorcontrib>Erickson, Mauri ; Boone, Tyler J ; Nadworny, Patricia L</creatorcontrib><description>Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.</description><identifier>ISSN: 1999-4915</identifier><identifier>EISSN: 1999-4915</identifier><identifier>DOI: 10.3390/v16060959</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Antiviral agents ; Care and treatment ; Communicable diseases ; Complications and side effects ; Diagnosis ; Drug resistance in microorganisms ; Evaluation ; Patient outcomes ; Public health administration</subject><ispartof>Viruses, 2024-06, Vol.16 (6)</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Erickson, Mauri</creatorcontrib><creatorcontrib>Boone, Tyler J</creatorcontrib><creatorcontrib>Nadworny, Patricia L</creatorcontrib><title>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</title><title>Viruses</title><description>Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.</description><subject>Antiviral agents</subject><subject>Care and treatment</subject><subject>Communicable diseases</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Drug resistance in microorganisms</subject><subject>Evaluation</subject><subject>Patient outcomes</subject><subject>Public health administration</subject><issn>1999-4915</issn><issn>1999-4915</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjE1LxDAYhIMouK4e_AcBr7a-TZO077EWVxcW9uB6kmVJ0qRE-qH9Av-99eOwB5nDPAwzQ8h1BGEcI9xNkQQJKPCELCJEDDhG4vSIz8lF378BSImQLMh91gx-8p2qaGa-afikraNZ-dqPOhT79fYH5P6WKvrS-I_R0mdfTbajeVu_t2NTXJIzp6reXv35kuxWD7v8KdhsH9d5tglKmcjAYGGl4kyhhtQVBRhpOHOo0oRxoTRoJkCmAhJtNFfcacswiouUMaZjcPGS3PzelqqyB9-4duiUqX1vDlmCKLmImJxb4T-tWYWtvWkb6_ycHw2-AN7KWPU</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Erickson, Mauri</creator><creator>Boone, Tyler J</creator><creator>Nadworny, Patricia L</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20240601</creationdate><title>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</title><author>Erickson, Mauri ; Boone, Tyler J ; Nadworny, Patricia L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g676-c9de6a42a9b08fdd0c6c42f9a87245ab0b25068507bcb4a4fbe2913d8222b30f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiviral agents</topic><topic>Care and treatment</topic><topic>Communicable diseases</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Drug resistance in microorganisms</topic><topic>Evaluation</topic><topic>Patient outcomes</topic><topic>Public health administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erickson, Mauri</creatorcontrib><creatorcontrib>Boone, Tyler J</creatorcontrib><creatorcontrib>Nadworny, Patricia L</creatorcontrib><jtitle>Viruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erickson, Mauri</au><au>Boone, Tyler J</au><au>Nadworny, Patricia L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</atitle><jtitle>Viruses</jtitle><date>2024-06-01</date><risdate>2024</risdate><volume>16</volume><issue>6</issue><issn>1999-4915</issn><eissn>1999-4915</eissn><abstract>Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.</abstract><pub>MDPI AG</pub><doi>10.3390/v16060959</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1999-4915 |
ispartof | Viruses, 2024-06, Vol.16 (6) |
issn | 1999-4915 1999-4915 |
language | eng |
recordid | cdi_gale_infotracmisc_A799645126 |
source | MDPI - Multidisciplinary Digital Publishing Institute; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
subjects | Antiviral agents Care and treatment Communicable diseases Complications and side effects Diagnosis Drug resistance in microorganisms Evaluation Patient outcomes Public health administration |
title | Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A14%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20Activity%20of%20Ag%5Bsub.5%5DIO%5Bsub.6%5D,%20a%20Unique%20Silver%20Compound&rft.jtitle=Viruses&rft.au=Erickson,%20Mauri&rft.date=2024-06-01&rft.volume=16&rft.issue=6&rft.issn=1999-4915&rft.eissn=1999-4915&rft_id=info:doi/10.3390/v16060959&rft_dat=%3Cgale%3EA799645126%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A799645126&rfr_iscdi=true |